Editas Medicine (EDIT) shares were up almost 7% in recent trading Monday after the company said that its renizgamglogene autogedtemcel, or reni-cel, therapy continued to be well-tolerated in sickle cell disease patients.
Updated data from the company's clinical trial showed that all 28 subjects with severe sickle cell disease showed a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant, Editas said.
The company also said that 27 of the patients experienced no vaso-occlusive events, that cause pain and other complications, while some patients showed improvements in markers such as hemoglobin levels and fetal hemoglobin.
Editas said it would present the updated clinical data at the American Society of Hematology annual meeting on Monday.
Price: 2.29, Change: +0.15, Percent Change: +6.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.